厄贝沙坦联合阿托伐他汀治疗早期糖尿病肾病合并心血管疾病效果观察

发布时间：2018-03-14 07:22

  本文选题：糖尿病肾病　切入点：心血管疾病　出处：《山东医药》2017年46期 　论文类型：期刊论文

【摘要】：目的探讨厄贝沙坦联合阿托伐他汀治疗早期糖尿病肾病(DN)合并心血管疾病患者的疗效。方法选取早期DN合并心血管疾病患者90例,分为观察组、对照1组、对照2组各30例。每组均予控制血压、控制血糖、预防感染及限制蛋白质摄入等常规治疗,对照1组予厄贝沙坦150 mg,1次/d口服;对照2组予阿托伐他汀40mg,1次/d口服;观察组将阿托伐他汀与厄贝沙坦联用。各组均连用6个月。治疗后评价临床疗效,计算总有效率。治疗前后检测血压(SBP、DBP)。治疗前后抽空腹静脉血,检测血脂指标(包括TG、TC、LDL-C、HDL-C)及血清B型脑钠肽(BNP)、同型半胱氨酸(Hcy)、肌钙蛋白I(c Tn I)、超敏C反应蛋白(hs-CRP)水平。结果观察组总有效率高于对照1、2组(P均0.05)。治疗后,观察组SBP、DBP均低于对照1、2组(P均0.05);观察组TC、TG、LDL-C水平均低于对照1、2组,HDL-C均高于对照1、2组(P均0.05);观察组血清BNP、HCY、cTnⅠ、hs-CRP水平均低于对照1、2组(P0.05或0.01)。结论厄贝沙坦联合阿托伐他汀治疗合并心血管疾病的早期DN患者可以提高临床疗效,降低血压以及改善血脂水平,且可降低血清BNP、HCY、cTnⅠ、hs-CRP水平。
[Abstract]:Objective to investigate the efficacy of irbesartan combined with Atto vastatin in the treatment of early diabetic nephropathy (DN) with cardiovascular disease. Methods 90 patients with early DN complicated with cardiovascular disease were divided into observation group and control group. Control group (n = 30) received routine therapy such as controlling blood pressure, controlling blood glucose, preventing infection and limiting protein intake. Control group 1 was given irbesartan 150 mg / d once a day, control group 2 was given once a / d Atto vastatin 40 mg / d. The observation group was treated with Atto vastatin and irbesartan for 6 months. The clinical effect was evaluated and the total effective rate was calculated after treatment. The blood pressure was measured before and after treatment, and the abdominal venous blood was emptied before and after treatment. The serum lipids (including TGG, TCU, LDL-C, HDL-C), B type brain natriuretic peptide (BNPP), homocysteine cystatin (Hcyl), troponin I (c Tn), hypersensitive C-reactive protein (hs-CRP) were measured. Results the total effective rate of the observation group was higher than that of the control group (P 0.05). After treatment, the total effective rate of the observation group was higher than that of the control group (P < 0.05). In the observation group, the levels of SBP and DBP were lower than those in the control group (P < 0.05), the LDL-C levels in the observation group were lower than those in the control group (n = 12), the levels of HDL-C in the observation group were higher than those in the control group (P < 0.05), and the serum levels of BNP-HCYTn 鈪，

本文编号：1610177